

Supplemental Information



Friedel-Crafts Alkylation with α -Bromo Arylacetates for the Preparation of Enantioenriched 2,2-Diarylethanol



Yongtae Kim,^a Yun Soo Choi,^a Su Kyung Hong,^a and Yong Sun Park^{*a}



Contents



I. NMR Spectra for 2-32



II. Chiral stationary phase HPLC chromatograms of 7-32




































































































































Compound 7: Chiralcel OD, 3% IPA/HXN, 0.5 ml/min





#	RT (min)	Peak Area (MV*Sec)	Peak Shape	Peak Width (sec)	Peak Area (%)
1	30.563	19979.037	VV	303.100	100.000

Compound 8: Chiralcel OD, 20% IPA/HXN, 0.5 ml/min




#	RT (min)	Peak Area (MV*Sec)	Peak Shape	Peak Width (sec)	Peak Area (%)
1	19.605	456.252	PP	122.900	0.368
2	36.378	123386.813	PV	382.000	99.632

Compound 9: Chiralcel OJ-H, 10% IPA/HXN, 0.5 ml/min




#	RT (min)	Peak Area (MV*Sec)	Peak Shape	Peak Width (sec)	Peak Area (%)
1	29.435	54970.516	BB	284.100	98.895
2	39.847	614.321	BB	108.100	1.105


Compound **10**: Chiralcel OD, 10% IPA/HXN, 0.5 ml/min




Compound **11**: Chiralcel OD, 10% IPA/HXN, 0.5 ml/min




Compound **12**: Chiralcel OD, 10% IPA/HXN, 0.5 ml/min




Compound **13**: Chiralcel OD, 10% IPA/HXN, 0.5 ml/min




Compound **14**: Chiralcel OD, 10% IPA/HXN, 0.5 ml/min




Compound **15**: Chiralcel OJ-H, 5% IPA/HXN, 0.5 ml/min




Compound **16**: Chiralcel OJ-H, 10% IPA/HXN, 0.5 ml/min




Compound **17**: Chiralcel OD, 20% IPA/HXN, 0.5 ml/min




Compound **18**: Chiralcel OD, 3% IPA/HXN, 0.5 ml/min




Compound **19**: Chiralcel OD, 10% IPA/HXN, 0.5 ml/min




Compound **20**: Chiralcel OD, 3% IPA/HXN, 0.5 ml/min




Compound **21**: Chiralcel OD, 10% IPA/HXN, 0.5 ml/min




Compound 22: Chiralcel OD, 10% IPA/HXN, 0.5 ml/min




Compound 23: Chiralcel OD, 10% IPA/HXN, 0.5 ml/min




Compound 24: Chiralcel OD, 10% IPA/HXN, 0.5 ml/min




Compound 25: Chiralcel OD, 10% IPA/HXN, 0.5 ml/min




Compound 26: Chiralcel OD, 5% IPA/HXN, 0.5 ml/min




Compound 27: Chiralcel OD, 10% IPA/HXN, 0.5 ml/min




Compound **28**: Chiralcel OD, 10% IPA/HXN, 0.5 ml/min




Compound **29**: Chiralcel OD, 10% IPA/HXN, 0.5 ml/min



Compound **30**: Chiralcel OJ-H 10% IPA/HXN, 0.5 ml/min



Compound **31**: Chiralcel OD, 10% IPA/HXN, 0.5 ml/min



Compound **32**: Chiralcel OD, 10% IPA/HXN, 0.6 ml/min

